Big announcement

1. CIMC Auto plans to buy back all issued H shares at a premium of about 4.90%. Trading will resume today

$CIMC VEHICLES (01839.HK)$According to the announcement, a conditional offer was proposed to repurchase all issued H shares, with a cash price of 7.5 yuan per share, a 4.9% premium over the pre-suspension price; the total value is about 1.1 billion yuan, which is to be disbursed using internal resources. After completion, the company withdrew the listing status of H shares on the Stock Exchange and plans to maintain the listing of A shares on the Shenzhen Stock Exchange. The company's shares have applied to resume trading on Tuesday (12th).

2. China Resources Land: cumulative contract sales in the first 2 months were 20.61 billion yuan, a year-on-year decrease of 48.8%

$CHINA RES LAND (01109.HK)$An announcement was issued. As of February 29, 2024, the group achieved a total contract sales volume of about RMB 9.19 billion and a total contract sales floor area of about 456,500 square meters, a decrease of 62.0% and 52.1%, respectively. In the same period, equity contract sales volume and equity contract sales floor area were about 6.45 billion yuan and 342,600 square meters respectively, decreasing by 65.0% and 53.2% year-on-year respectively. The cumulative contract sales volume for 2024 was approximately RMB 20.61 billion, and the total contract sales area was about 986,800 square meters, a year-on-year decrease of 48.8% and 40.8%, respectively.

3. Pharmacist Help released annual results, with revenue of about 16.972 billion yuan, an increase of 18.9% over the previous year

$YSB (09885.HK)$The results for the year ended December 31, 2023 were announced, with revenue of approximately RMB 16.972 billion (RMB, same below), up 18.9% year on year; gross profit of RMB 1,741 billion, up 21.3% year on year; adjusted net profit of about RMB 131 million, compared with adjusted loss of 125 million yuan in the same period in 2022; total commodity transaction volume reached RMB 46.912 billion, up 24% year on year.

4. Sinopec Oil Services Performance Report: 2023 net profit of 590 million yuan, up 23.8% year on year

$SINOPEC SSC (01033.HK)$The 2023 annual performance report was announced. In 2023, international crude oil prices remained generally medium to high, oil companies continued to increase investment in upstream exploration and development, and the oilfield service industry continued to pick up. Affected by this, the company's main professional workload and team utilization rate have increased to varying degrees. The company's consolidated revenue was RMB 79.98 billion, up 8.4% year on year; net profit attributable to shareholders of the company was RMB 590 million, up 23.8% year on year.

5. Laikai Pharmaceutical-B submits a clinical trial application for a new drug for obesity to the US Food and Drug Administration

$LAEKNA-B (02105.HK)$According to the announcement, the group has submitted a new drug clinical trial application (IND) for LAE102 to the US Food and Drug Administration. The drug is a monoclonal antibody developed independently by Lai Kai to treat adult patients with obesity or metabolic diseases.

The company will work closely with regulators to complete the application process. The company is committed to providing precise treatment for patients with obesity or metabolic diseases who require novel treatment options.

Earnings Report

$SINOPEC SSC (01033.HK)$Performance report: 2023 net profit of 590 million yuan increased 23.8% year-on-year

$YSB (09885.HK)$Annual results were released, with revenue of about 16.972 billion yuan, an increase of 18.9% over the previous year

$TUYA-W (02391.HK)$Announcement of annual results Overall gross margin rose to 46.4% and reached annual balance of payments for the first time

$MODERN DENTAL (03600.HK)$Yingxi: Net profit is expected to increase by about 76.5% to 85.5% year on year in 2023

$SF INTRA-CITY (09699.HK)$Yingxi: Net profit from continuing operations is expected to be no less than 60 million yuan in 2023

$SHENZHEN INVEST (00604.HK)$Profit Alert: Expected consolidated loss of HK$248 million to HK$406 million to equity shareholders in fiscal year 2023

Operational data

$CHINA LIFE (02628.HK)$: The cumulative original premium income of 252.7 billion yuan in January-February increased 2.8% year-on-year

$CHINA RES LAND (01109.HK)$: In the first 2 months, cumulative contract sales amounted to 20.61 billion yuan, a year-on-year decrease of 48.8%

$YUE YUEN IND (00551.HK)$: Net consolidated operating income of US$606 million for February

$GREENLAND HK (00337.HK)$Contract sales for the first two months were approximately $1.31 billion

$GANGLONG CHINA (06968.HK)$In February, the contract sales amount was approximately 1,086 million yuan

$SINO-OCEAN GP (03377.HK)$: February agreed sales of 820 million yuan

$COFCO JOYCOME (01610.HK)$Operation Report: 204,000 pigs were released in February

Pharmaceutical Innovation

$SINO BIOPHARM (01177.HK)$Data from 5 studies on “anlotinib hydrochloride capsules” and “TQB2916 (CD40 agonist)” will be announced in 2024AACR

$LAEKNA-B (02105.HK)$: A new drug clinical trial application for LAE102 has been submitted to the US Food and Drug Administration to treat adult patients with obesity or metabolic diseases

$SH PHARMA (02607.HK)$: I040 clinical trial application accepted

$SKB BIO-B (06990.HK)$: The main product A400 (EP0031) was granted Fast Track Qualification by the US FDA

Increase or decrease holdings

$DONGFENG GROUP (00489.HK)$: Dongfeng Motor increased its H share holdings by 24.99 million shares

Repurchase cancellation

$ARRAIL GROUP (06639.HK)$It is planned to use up to HK$200 million to implement the share repurchase scheme

$STANCHART (02888.HK)$On March 8, it cost £21.5088 million to buy back 3.253,000 shares

$HSBC HOLDINGS (00005.HK)$On March 8, it cost HK$142 million to repurchase 2.4056 million shares

$WUXI APPTEC (02359.HK)$Initial repurchase of 937,000 company shares

$SWIRE PACIFIC A (00019.HK)$On March 11, it cost HK$12.72 million to repurchase 199,500 shares

$AIA (01299.HK)$On March 11, it cost HK$6.2912 million to buy back 101,400 shares

$BAIRONG-W (06608.HK)$17.18 million shares cancelled on March 11

edit/new